TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12766931

Group type: EXPERIMENTAL
Intervention: Nefazodone 100mg bd
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study: 10489824

Group type: EXPERIMENTAL
Intervention: Leukotriene antagonist
Number of subjects: 281

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 281
Study: 8728530

Group type: EXPERIMENTAL
Intervention: Air-Stirrup brace
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Adhesive tape
Number of subjects: 26

Group type: COMPARATOR
Intervention: No support (control)
Number of subjects: 26
Study: 1713987

Group type: EXPERIMENTAL
Intervention: Nicardipine (0.06 mg/kg/min)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 6981165

Group type: EXPERIMENTAL
Intervention: Antimicrobial prophylaxis alone (trimethoprim‐sulfamethoxazole or nitrofurantoin)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Antimicrobial prophylaxis plus corrective surgery
Number of subjects: 30

Group type: COMPARATOR
Intervention: Antimicrobial prophylaxis alone (control group)
Number of subjects: 30
Study: 2580712

Group type: EXPERIMENTAL
Intervention: Lorcainide (2 mg/kg)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Lidocaine (100 mg)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 29481391

Group type: EXPERIMENTAL
Intervention: Intraoperative intercostal and pectoral nerve blocks with 0.25% bupivacaine with 1:200,000 epinephrine and 4 mg of dexamethasone
Number of subjects: 47

Group type: COMPARATOR
Intervention: Sham nerve blocks with normal saline
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Intraoperative intercostal and pectoral nerve blocks
Number of subjects: 47
Study: 27855103

Group type: EXPERIMENTAL
Intervention: Hyaluronic acid (HA)‐selection of sperm (physiological intracytoplasmic sperm injection, PICSI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional sperm selection methods (ICSI)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hyaluronic acid (HA)‐selection of sperm
Number of subjects: 0
Study: 25336055

Group type: EXPERIMENTAL
Intervention: Thoracic Epidural Analgesia (TEA)
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Rectus Sheath Catheters (RSC)
Number of subjects: 132
Study: 23563024

Group type: EXPERIMENTAL
Intervention: n‐3 PUFA 1 g daily
Number of subjects: 52

Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 52
Study: 20681808

Group type: EXPERIMENTAL
Intervention: Immediate loading
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional loading
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study: 17962632

Group type: EXPERIMENTAL
Intervention: Lung volume reduction surgery (LVRS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Medical cohort (control)
Number of subjects: 0
Study: 17491171

Group type: EXPERIMENTAL
Intervention: Internet-administered questionnaires
Number of subjects: 213

Group type: COMPARATOR
Intervention: Telephone-administered questionnaires
Number of subjects: 213
Study: 14605015

Group type: EXPERIMENTAL
Intervention: Antithrombotic therapy (enoxaparin or unfractionated heparin in combination with tirofiban or placebo) for 2 to 8 days in TETAMI randomized patients.
Number of subjects: 2737

Group type: EXPERIMENTAL
Intervention: Reperfusion therapy (lytic or primary PCI) in registry patients who received reperfusion.
Number of subjects: 2737

Group type: COMPARATOR
Intervention: Registry patients who did not receive reperfusion therapy.
Number of subjects: 2737
Study: 11027741

Group type: EXPERIMENTAL
Intervention: 10 mg of melatonin
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: 10 mg of melatonin followed by 0.5 mg per day
Number of subjects: 7
Study: 8914777

Group type: EXPERIMENTAL
Intervention: Magnesium therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 1410588

Group type: EXPERIMENTAL
Intervention: Nicotinamide (1-6 g oral doses)
Number of subjects: 4
Study: 6232524

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nicotine chewing-gum
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 31522217

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided continuous fascia iliaca compartment block (FICB) for preoperative analgesia
Number of subjects: 85

Group type: COMPARATOR
Intervention: Fake (or generic) continuous FICB
Number of subjects: 85
Study: 30256065

Group type: EXPERIMENTAL
Intervention: Exergaming protocol using Xbox 360® with Kinect® and the game 'Your Shape Fitness Evolved'
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group (no exergaming)
Number of subjects: 38
Study: 27067706

Group type: EXPERIMENTAL
Intervention: Multilevel urine pregnancy test (MLPT)
Number of subjects: 600

Group type: COMPARATOR
Intervention: High sensitivity urine pregnancy test (HSPT)
Number of subjects: 600
Study: 25300037

Group type: EXPERIMENTAL
Intervention: START intervention (manual-based coping strategy programme)
Number of subjects: 260
Study: 22994617

Group type: EXPERIMENTAL
Intervention: Motor intervention programme (60 minutes of exercises, three times per week for 6 months)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Motor intervention programme
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (no motor intervention)
Number of subjects: 32
Study: 19826403

Group type: EXPERIMENTAL
Intervention: Rexin-G (dose 0-1)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Rexin-G (dose 2)
Number of subjects: 9
Study: 16614849

Group type: EXPERIMENTAL
Intervention: Gemcitabine (1,200 mg/m²) as a 2-h continuous infusion (10 mg/m² per min) on days 1 and 8 of each cycle plus AUC 5 carboplatin on day 1, repeated every 21 days.
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Gemcitabine plus carboplatin
Number of subjects: 54
Study: 16099700

Group type: EXPERIMENTAL
Intervention: Tigecycline monotherapy
Number of subjects: 573

Group type: COMPARATOR
Intervention: Vancomycin plus Aztreonam (V + A)
Number of subjects: 573
Study: 12351535

Group type: EXPERIMENTAL
Intervention: NuvaRing used for 3 weeks (Group A)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: NuvaRing used for 3 days (Group B)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: NuvaRing with monitoring until a follicle of 13 mm (Group C)
Number of subjects: 45
Study: 9471048

Group type: EXPERIMENTAL
Intervention: Intracavernous injection (ICI) of etilefrin
Number of subjects: 156
Study: 7657903

Group type: EXPERIMENTAL
Intervention: Practice Guidelines Nutrition Care (PGC)
Number of subjects: 179

Group type: COMPARATOR
Intervention: Basic Nutrition Care (BC)
Number of subjects: 179
Study: 2676659

Group type: EXPERIMENTAL
Intervention: 10 g fish oil concentrate (30% omega 3FAs) daily
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 10 g safflower oil daily
Number of subjects: 10

Group type: COMPARATOR
Intervention: no supplementation (baseline)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: fish oil
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: safflower oil
Number of subjects: 10
Study: 201203

Group type: EXPERIMENTAL
Intervention: Sex hormone treatment
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Calcium carbonate (CaCO3) treatment
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study: 31429198

Group type: EXPERIMENTAL
Intervention: Arthroscopic partial meniscectomy
Number of subjects: 351

Group type: COMPARATOR
Intervention: Physical therapy
Number of subjects: 351

Group type: EXPERIMENTAL
Intervention: Arthroscopic partial meniscectomy (as-treated)
Number of subjects: 351

Group type: COMPARATOR
Intervention: Nonoperative treatment (as-treated)
Number of subjects: 351
Study: 31031579

Group type: EXPERIMENTAL
Intervention: Anodal HD-tDCS
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Cathodal HD-tDCS
Number of subjects: 18

Group type: COMPARATOR
Intervention: Sham HD-tDCS
Number of subjects: 18
Study: 28994678

Group type: EXPERIMENTAL
Intervention: Insulin (continuous infusion)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Metformin (500 mg tablets twice daily)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Insulin
Number of subjects: 56
Study: 26223240

Group type: EXPERIMENTAL
Intervention: CHOICE diet (60% carbohydrate/25% fat/15% protein)
Number of subjects: 12

Group type: COMPARATOR
Intervention: LC/CONV diet (40% carbohydrate/45% fat/15% protein)
Number of subjects: 12
Study: 24410251

Group type: EXPERIMENTAL
Intervention: RRR‐HIV intervention (HIV educational video, five group sessions, one postrelease booster session)
Number of subjects: 444

Group type: COMPARATOR
Intervention: Control condition (HIV educational video)
Number of subjects: 444
Study: 22890220

Group type: EXPERIMENTAL
Intervention: Telephone-based exercise intervention
Number of subjects: 130

Group type: COMPARATOR
Intervention: Wellness/support contact control
Number of subjects: 130
Study: 19321398

Group type: EXPERIMENTAL
Intervention: Primary closure of CBD
Number of subjects: 35

Group type: COMPARATOR
Intervention: T-tube drainage
Number of subjects: 35
Study: 17250464

Group type: EXPERIMENTAL
Intervention: Panitumumab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lapatinib
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sunitinib
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sorafenib
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Erlotinib
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bevacizumab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cetuximab
Number of subjects: 0
Study: 15736476

Group type: EXPERIMENTAL
Intervention: TXT plus CBG
Number of subjects: 70

Group type: COMPARATOR
Intervention: TXT alone
Number of subjects: 70
Study: 11554671

Group type: EXPERIMENTAL
Intervention: Subtle activation of positive stereotypes
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Subtle activation of negative stereotypes
Number of subjects: 3

Group type: COMPARATOR
Intervention: Children in upper elementary grades (grades 3‐5)
Number of subjects: 3
Study: 9371205

Group type: EXPERIMENTAL
Intervention: Parental smoking habits (not specified dosage or duration)
Number of subjects: 501

Group type: EXPERIMENTAL
Intervention: Parental cotinine levels and amount smoked in the home
Number of subjects: 501

Group type: EXPERIMENTAL
Intervention: Home environment (presence of a garden)
Number of subjects: 501
Study: 7631069

Group type: EXPERIMENTAL
Intervention: Fetal dopaminergic tissue implants by the open microsurgical technique
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Fetal mesencephalic cell suspension transplants (7 unilateral and 9 bilateral)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Stereotactic selective thalamotomy with microelectrode recording
Number of subjects: 46
Study: 3681498

Group type: EXPERIMENTAL
Intervention: 250 ppm acetone
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: 200 ppm methyl ethyl ketone
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: 125 ppm acetone/100 ppm methyl ethyl ketone
Number of subjects: 70

Group type: COMPARATOR
Intervention: chemical placebo
Number of subjects: 70
Study: 30048341

Group type: EXPERIMENTAL
Intervention: Trial fitting group (group A)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Software fitting group (group B)
Number of subjects: 100
Study: 25922474

Group type: EXPERIMENTAL
Intervention: Day surgery
Number of subjects: 78

Group type: COMPARATOR
Intervention: One night hospital stay
Number of subjects: 78
Study: 25730930

Group type: EXPERIMENTAL
Intervention: Physical training (natural walking at 60% of maximum heart rate)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Control group (medicamental therapy only)
Number of subjects: 110
Study: 22913492

Group type: EXPERIMENTAL
Intervention: (90)Y‐RE
Number of subjects: 140

Group type: COMPARATOR
Intervention: TACE
Number of subjects: 140
Study: 20005079

Group type: EXPERIMENTAL
Intervention: Antiepileptic drug treatment
Number of subjects: 125
Study: 17076917

Group type: EXPERIMENTAL
Intervention: Cognitive self-therapy (CST)
Number of subjects: 151

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 151
Study: 16383096

Group type: EXPERIMENTAL
Intervention: Intervention program based on the Theory of Planned Behavior, including posters and lectures promoting healthy eating for 12 weeks
Number of subjects: 335

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 335
Study: 12062150

Group type: EXPERIMENTAL
Intervention: Electrophysiological correlates of conscious change detection
Number of subjects: 0

Group type: COMPARATOR
Intervention: Electrophysiological correlates of change blindness
Number of subjects: 0
Study: 7783410

Group type: EXPERIMENTAL
Intervention: Cyclosporine (D)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 64
Study: 2203556

Group type: EXPERIMENTAL
Intervention: Aspirin (325 mg, alternate-day intake)
Number of subjects: 22071

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22071
Study: 360766

Group type: EXPERIMENTAL
Intervention: Thiethylperazine 6.5 mg, 2 capsules a day for 5 days
Number of subjects: 40

Group type: COMPARATOR
Intervention: Meclizine 25 mg, 2 capsules a day for 5 days
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both interventions (Thiethylperazine and Meclizine)
Number of subjects: 40
Study: 31596244

Group type: EXPERIMENTAL
Intervention: Telemedical emergency service
Number of subjects: 6265
Study: 27860389

Group type: EXPERIMENTAL
Intervention: Canrenone 50 mg
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Canrenone 100 mg
Number of subjects: 175
Study: 26845030

Group type: EXPERIMENTAL
Intervention: Interpersonal psychotherapy (IPT) plus treatment as usual (TAU)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment as usual (TAU) alone
Number of subjects: 0
Study: 23510444

Group type: EXPERIMENTAL
Intervention: Lithium treatment (mean weight-adjusted total daily dose at end of phase II was 27.8 mg/kg/day, average lithium concentration of 1.0 mEq/L)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Adjunctive psychotropic medications (up to two could be prescribed)
Number of subjects: 41
Study: 20558528

Group type: EXPERIMENTAL
Intervention: High-intensity exercise (HE)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Moderate intensity exercise (ME)
Number of subjects: 90

Group type: COMPARATOR
Intervention: No exercise/rest (NE)
Number of subjects: 90
Study: 19576495

Group type: EXPERIMENTAL
Intervention: Monocular therapy with latanoprost
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Monocular trial eye
Number of subjects: 26
Study: 17241503

Group type: EXPERIMENTAL
Intervention: Lidocaine 0.5 mg kg(‐1) (Group 3)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.25 microg kg(‐1) plus lidocaine 0.25 mg kg(‐1) (Group 4)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.25 microg kg(‐1) plus lidocaine 0.5 mg kg(‐1) (Group 5)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Saline (Group 1)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.25 microg kg(‐1) (Group 2)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Overall incidence of withdrawal movements due to rocuronium
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Incidence of withdrawal movement after rocuronium injection
Number of subjects: 150
Study: 15017827

Group type: EXPERIMENTAL
Intervention: Approach-focused RP intervention
Number of subjects: 47

Group type: COMPARATOR
Intervention: Avoidance-focused RP intervention
Number of subjects: 47
Study: 11136682

Group type: EXPERIMENTAL
Intervention: Intervention group (lifestyle changes)
Number of subjects: 275

Group type: COMPARATOR
Intervention: Assessment-only group (control)
Number of subjects: 275
Study: 9681721

Group type: EXPERIMENTAL
Intervention: Haemodiafiltration with backfiltration (Group II, 12 patients)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Haemodiafiltration without backfiltration (Group I, 16 patients)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Haemodiafiltration with backfiltration (Group III, 27 patients)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Haemodialysis (Group IV, 10 patients)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Healthy volunteers (Group V, 10 patients)
Number of subjects: 65
Study: 7973771

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy with cisplatin 50 mg/m2 days 1 and 8 every 4 weeks during the 16 weeks, and vinorelbine 30 mg/m2 weekly for 16 weeks.
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Vinorelbine 30 mg/m2 weekly for 5 weeks with a 50% dose reduction planned for week 2 only, in combination with cisplatin 100 mg/m2 during weeks 1 and 5, and accelerated fractionation thoracic irradiation during weeks 7 to 10.
Number of subjects: 17

Group type: COMPARATOR
Intervention: Observation (control group).
Number of subjects: 17
Study: 2529150

Group type: EXPERIMENTAL
Intervention: Betamethasone 17,21‐dipropionate (Bet) and fluprednidene 21‐acetate (Flu) applied in a 1:1 and 1:2 rhythm under occlusive dressing for 8 weeks.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Continuous application (CA) of Bet and Flu for 3 weeks.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hydrocortisone 17‐butyrate, betamethasone 17‐valerate, desoxymethasone, and hydrocortisone tested in a 5:9 regimen under occlusive dressing for 3 months.
Number of subjects: 0
Study: 5090667

Group type: EXPERIMENTAL
Intervention: Water miscible preparation of α‐tocopheryl acetate, daily dose of 1 mg/kg body weight
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fat soluble preparation of α‐tocopheryl acetate
Number of subjects: 0
Study: 31725319

Group type: EXPERIMENTAL
Intervention: High sodium intake (15 g/day for 7 days)
Number of subjects: 13
Study: 31306302

Group type: EXPERIMENTAL
Intervention: 30FAIL (30% 1RM to volitional fatigue)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: 80FAIL (80% 1RM performed to volitional fatigue)
Number of subjects: 21

Group type: COMPARATOR
Intervention: 30WM (30% 1RM with volume matched to 80FAIL)
Number of subjects: 21
Study: 28101947

Group type: EXPERIMENTAL
Intervention: Er:YAG laser (ERL)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Plastic curettes + cotton pellets + sterile saline (CPS)
Number of subjects: 15
Study: 24794517

Group type: EXPERIMENTAL
Intervention: SMR neurofeedback training
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sham feedback
Number of subjects: 20
Study: 23521322

Group type: EXPERIMENTAL
Intervention: Niacin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 21603848

Group type: EXPERIMENTAL
Intervention: Modified constraint-induced movement therapy
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Intensive conventional rehabilitation
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional rehabilitation
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 30
Study: 19531784

Group type: EXPERIMENTAL
Intervention: Polymyxin B hemoperfusion (2 sessions)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 64
Study: 17074775

Group type: EXPERIMENTAL
Intervention: Ularitide at 7.5 ng/kg/min
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Ularitide at 15 ng/kg/min
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Ularitide at 30 ng/kg/min
Number of subjects: 221

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 221
Study: 15063145

Group type: EXPERIMENTAL
Intervention: Simultaneous Communication (SC)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Speech Alone (SA)
Number of subjects: 12
Study: 11179544

Group type: EXPERIMENTAL
Intervention: Second-generation dihydropyridine calcium channel blockers
Number of subjects: 0
Study: 9258853

Group type: EXPERIMENTAL
Intervention: 8% carbohydrate solution
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo solution
Number of subjects: 8
Study: 8070007

Group type: EXPERIMENTAL
Intervention: Epirubicin (75 mg/m2) administered intravenously
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Epirubicin (75 mg/m2) administered via hepatic artery
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Lignocaine (1 mg/kg) administered intravenously
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Epirubicin (75 mg/m2)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Intravenous epirubicin
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Intraarterial epirubicin
Number of subjects: 16
Study: 3343920

Group type: EXPERIMENTAL
Intervention: Hydrostatic weighing (HW) at residual volume (RV)
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Hydrostatic weighing (HW) at total lung capacity without head submersion (TLCNS)
Number of subjects: 182

Group type: COMPARATOR
Intervention: Db from HW at RV
Number of subjects: 182

Group type: COMPARATOR
Intervention: pDb from HW at TLCNS
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Test-re-test data for TLCNS procedure
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Mean percent fat for RV and TLCNS
Number of subjects: 182
Study: 31738621

Group type: EXPERIMENTAL
Intervention: FDA approved medications for IBS-D
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Emerging therapies for IBS-D
Number of subjects: 0
Study: 29630479

Group type: EXPERIMENTAL
Intervention: Occupational sitting time (measured with activPAL3 monitor)
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Occupational standing and stepping time (measured with activPAL3 monitor)
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Total activity duration
Number of subjects: 216
Study: 28365177

Group type: EXPERIMENTAL
Intervention: Vitamin D (cholecalciferol; 100,000 IU, once-monthly)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study: 24689780

Group type: EXPERIMENTAL
Intervention: Massage therapy
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 25
Study: 23982218

Group type: EXPERIMENTAL
Intervention: Vanadyl sulfate 25 mg V daily
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Vanadyl sulfate 50 mg V daily
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Vanadyl sulfate 100 mg V daily
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Euglycemic‐hyperinsulinemic clamp
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Globulin and glycohemoglobin levels
Number of subjects: 16
Study: 21358385

Group type: EXPERIMENTAL
Intervention: Systematic Care Program for Dementia (SCPD)
Number of subjects: 295

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 295